VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

25 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Participate in Upcoming Investor Conferences

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

07 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference

02 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

10 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

18 May 2023 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

09 May 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors

09 May 2023 06:55:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

02 May 2023 16:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference

28 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

07 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Participate in Upcoming Investor Conferences

09 Feb 2023 07:00:01 By Nasdaq GlobeNewswire